|
業務類別
|
Biotechnology |
|
業務概覽
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
| 公司地址
| 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932 |
| 電話號碼
| +1 877 742-8466 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.phathompharma.com |
| 員工數量
| 371 |
| Mr. Sanjeev Narula |
Chief Financial and Business Officer |
-- |
26/02/2026 |
| Mr. Steven L. Basta |
Director, President and Chief Executive Officer |
-- |
26/02/2026 |
| Mr. Robert Charles Breedlove |
Vice President, Finance and Principal Accounting Officer |
-- |
06/10/2025 |
| Mr. Jonathan Bentley |
Senior Vice President and Head of Sales |
-- |
26/02/2026 |
|
|
| Mr. Frank L. Karbe |
Independent Director |
26/02/2026 |
| Mr. Steven L. Basta |
Director, President and Chief Executive Officer |
26/02/2026 |
| Mr. Theodore R. Schroeder |
Independent Director |
26/02/2026 |
| Dr. James N. Topper, M.D.,PhD |
Independent Director |
26/02/2026 |
| Ms. Heidi Kunz |
Independent Director |
26/02/2026 |
| Dr. Asit Parikh, M.D.,PhD |
Independent Director |
26/02/2026 |
| Mr. Mark Stenhouse |
Independent Director |
26/02/2026 |
| Mr. Michael F. Cola |
Chairman of the Board |
26/02/2026 |
|
|
|
|
